Phase 2Active, not recruitingINTERVENTIONAL
Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
ClinicalTrials.gov · NCT03796884 · Registry updated: 2026-10-08
- Condition / research focus
- Colorectal Adenoma; Stage 0 Colorectal Cancer AJCC v8; Stage I Colorectal Cancer AJCC v8; Stage II Colorectal Cancer AJCC v8; Stage IIA Colorectal Cancer AJCC v8; Stage IIB Colorectal Cancer AJCC v8; Stage IIC Colorectal Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2019-10-30. Completion: 2027-01 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Linaclotide (drug) — also listed as: 851199-59-2, Linzess, [9-L-tyrosine]heat-stable enterotoxin (Escherichia coli)-(6-19)-peptide, L-Tyrosine, L-cysteinyl-L-cysteinyl-L-alpha-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L- asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteiny, cyclic (1->6), (2->10), (5->13)-tris(disulfide), MD-1100
- Placebo (other)
Where the study takes place — 3 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported - Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported - VA Puget Sound Health Care Sysem
Seattle, Washington, United States
Site recruitment: Not reported